KR890011851A - 이소 키놀린 유도체, 그 제조방법 및 사용방법 - Google Patents

이소 키놀린 유도체, 그 제조방법 및 사용방법 Download PDF

Info

Publication number
KR890011851A
KR890011851A KR1019890000151A KR890000151A KR890011851A KR 890011851 A KR890011851 A KR 890011851A KR 1019890000151 A KR1019890000151 A KR 1019890000151A KR 890000151 A KR890000151 A KR 890000151A KR 890011851 A KR890011851 A KR 890011851A
Authority
KR
South Korea
Prior art keywords
dimethoxy
phenyl
hydrogen
compound
dihydrodo
Prior art date
Application number
KR1019890000151A
Other languages
English (en)
Other versions
KR0142686B1 (ko
Inventor
헤스페춰 클라우스
네이프 레토
Original Assignee
예안 클라메트 한스 루돌프 하우스
산도즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 예안 클라메트 한스 루돌프 하우스, 산도즈 리미티드 filed Critical 예안 클라메트 한스 루돌프 하우스
Publication of KR890011851A publication Critical patent/KR890011851A/ko
Application granted granted Critical
Publication of KR0142686B1 publication Critical patent/KR0142686B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

내용 없음

Description

이소 키놀린 유도체, 그 제조방법 및 사용방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 하기식(Ⅰ)의 화합물 또는 그 산부가염.
    (Ⅰ)
    상기식에서 R1은 수소 또는 C1-4알킬이고; R2는 수소이고; R3는 수소 또는 R1-4알킬이고; 또는 R2및 R3는 함께 점선으로 나타낸것처럼 부가결합을 나타내고; R4는 수소, C1-4알킬 또는 페닐이고; R5는 메톡시 또는 에톡시이고 ; R6는 수소, 히드록시, C1-4알콕시, 히드록시-(C2-4알콕시) 또는 (C1-4알콕시)-(C2-4알코시)이고 ; R7및 R8은 각각 독립적으로 C1-4알콕시 또는 (C1-4알콕시)-(C2-4알콕시)이고 ; 또한 R9는 수소 또는 할로겐이다.
  2. 제1항에 있어서, 상기 R1내지 R8이 제1항에서 정의한 바와 같고, R9가 수소인 식(Ⅰ)의 화합물, 또는 그 산부가염.
  3. 하기로 구성된 그룹으로부터 선택된 화합물, 또는 그 산부가염. 3-메틸-6,7-디메톡시-1-(3,5-디메톡시에톡시-페닐)-3,4-디히도로-이소키놀린, 3-페닐-6,7-디메톡시-1-(3,5-디메톡시에톡시-페닐)-3,4-디히도로-이소키놀린, 6,7-디메톡시-1-(3,5-디메톡시-페닐)-(3,4-디히드로-이소키놀린, 6,7-디에톡시-1-(3,5-디메톡시-페닐)-3,4-디히도로-이소키놀린, 4-메틸-6,7-디메톡시-1-(3,5-디메톡시-페닐)-3,4-디히도로-이소키놀린, 3-메틸-6,7-디메톡시-1-(3,5-디메톡시-페닐)-3,4-디히도로-이소키놀린, 3-에틸-6,7-디메톡시-1-(3,5-디메톡시-페닐)-3,4-디히도로-이소키놀린, 3-n프로필-6,7-디메톡시-1-(3,5-디메톡시-페닐)-3,4-디히도로-이소키놀린, 3,3-디메틸-6,7-디메톡시-1-(3,5-디메톡시-페닐)-3,4-디히도로-이소키놀린, 7-메톡시-6-메톡시-에톡시-1-(3,5-디메톡시-페닐)-3,4-디히도로-이소키놀린, 6-히드록시-7-디메톡시-1-(3,5-디메톡시-페닐)-3,4-디히도로-이소키놀린, 6,7-디메톡시-1-(3,5-디메톡시-페닐)-이소키놀린, 3-메틸-6,7-디메톡시-1-(3,5-디메톡시-페닐)-이소키놀린, 4- 매탈-6,7-디메톡시-1-(3,5-디메톡시-페닐)-이소키놀린, 1,4-디메틸-6,7-디메톡시-1-(3,5-디메톡시-페닐)-이소키놀린, 3-에틸-6,7-디메톡시1-(3,5-디메톡시-페닐)-이소키놀린, 3-n-프로필-6,7-디메톡시-1-(3,5-디메톡시-페닐)-이소키놀린,3-메틸-6-디메톡시-에톡시-7-메톡시-1-[3,5-디(메톡시에톡시)-페닐]-이소키놀린, 3-메틸-6-β-히드록시-에톡시-7-메톡시-1-[3,5-디(메톡시에톡시)-페닐]-이소키놀린.
  4. 3-메틸-6,7-디메톡시-1-(3,5-(디메톡시에톡시-4-브로모-페닐)-3,4-디히드로이소키놀린 및 3-메틸-6,7-디메톡시-1-[3.5-디(메톡시에톡시)-4-브로모페닐]-이소키놀린 및 그 산부가염으로 부터 선택된 화합물.
  5. 3-메틸-6,7-디메톡시-1-(3,5-디메톡시에톡시-페닐)-이소키놀린, 또는 가 산부가염.
  6. a) 하기식 (Ⅱ)의 화합물을 탈수 고리화시키고, 필요하다면 R5및 R'6에 존재하는 보호기를 제거하여 R2가 수소이고, R3가 수소 또는 C1-4알킬인 상응하는 식 (Ⅰ)의 화합물을 제조하고; b) R2및 R3가 각각 수소인 식 (Ⅰ)의 화합물을 탈수소화 시켜, R2및 R3가 함께 부가결합을 나타내는 상응하는 식(Ⅰ)의 화합물을 제조하고, 또는 수득한 식(Ⅰ)의 화합물을 유리 또는 산부가염 형태로 회수하는 것을 포함하는 것을 특징으로 하는 하기식 (Ⅰ)의 화합물 또는 그 산부가염의 제조방법.(Ⅰ)
    식중, R1내지 R9는 제1항에서 정의한바와 같다.
    (Ⅱ)
    상기식에서 R'2는 수소이고, R'3는 수소 또는 C1-4알킬이고, R'5및 R6는 히드록시기가 보호된 형태로 존재한다는 조건하에 식(Ⅰ)에서 정의한 R5및 R6와 동일한 의미를 가지며, R1, R4,R7, R8및 R5=상기식 (Ⅰ)에서 정의한 바와 같다.
  7. 제1항 내지 제5항에 기술된 화합물 또는 그 약학적 허용 산부가염과 함께 약학적으로 허용되는 희석제 또는 담체를 포함하는 약학조성물.
  8. 제1항 내지 5항중 어느 한항에 있어서, 약제로서 사용되는 화합물 또는 그 약학적 허용 산부가염.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890000151A 1988-01-08 1989-01-07 이소 퀴놀린 유도체, 및 이의 약학적 용도 KR0142686B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888800397A GB8800397D0 (en) 1988-01-08 1988-01-08 Improvements in/relating to organic compounds
GB8800397 1988-01-08

Publications (2)

Publication Number Publication Date
KR890011851A true KR890011851A (ko) 1989-08-22
KR0142686B1 KR0142686B1 (ko) 1998-07-15

Family

ID=10629678

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890000151A KR0142686B1 (ko) 1988-01-08 1989-01-07 이소 퀴놀린 유도체, 및 이의 약학적 용도

Country Status (28)

Country Link
US (1) US4980359A (ko)
JP (1) JPH0649686B2 (ko)
KR (1) KR0142686B1 (ko)
AT (1) AT394365B (ko)
AU (1) AU622429B2 (ko)
BE (1) BE1002730A3 (ko)
CA (1) CA1332944C (ko)
CH (1) CH678727A5 (ko)
DE (1) DE3900233C2 (ko)
DK (1) DK5789A (ko)
ES (1) ES2010071A6 (ko)
FI (1) FI90865C (ko)
FR (1) FR2625743B1 (ko)
GB (2) GB8800397D0 (ko)
GR (1) GR1002750B (ko)
HU (1) HU205083B (ko)
IE (1) IE61914B1 (ko)
IL (1) IL88899A (ko)
IT (1) IT1229523B (ko)
LU (1) LU87423A1 (ko)
MY (1) MY103963A (ko)
NL (1) NL8900029A (ko)
NZ (1) NZ227561A (ko)
PH (1) PH25640A (ko)
PL (1) PL156099B1 (ko)
PT (1) PT89405B (ko)
SE (1) SE501548C2 (ko)
ZA (1) ZA89133B (ko)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2723674A (en) * 1951-11-28 1955-11-15 Charles E Harris Telephone cableman's tent
US3007541A (en) * 1959-02-24 1961-11-07 Jr John B Mast Temporary covering and support structure therefor
GB8807922D0 (en) * 1988-04-05 1988-05-05 Fujisawa Pharmaceutical Co Isoquinoline compound & process for preparation thereof
US4956371A (en) * 1989-09-19 1990-09-11 Euroceltique, S.A. Substituted isoquinolines and methods of using same
GB8921304D0 (en) * 1989-09-20 1989-11-08 Wyeth John & Brother Ltd New method of treatment and heterocyclic compounds used therein
GB9027055D0 (en) * 1990-12-13 1991-02-06 Sandoz Ltd Organic compounds
KR930703259A (ko) * 1990-12-17 1993-11-29 알베르투스 빌헬무스 요아네스 쩨스트라텐 살균성 이소퀴놀린 유도체
CA2093577C (en) * 1992-05-07 2006-01-03 Michael Klaus Alkyl or alkoxy substituted s-heterocyclic retinoids
US5350423A (en) * 1992-09-23 1994-09-27 Burlington Industries Inc. Fabric finishing procedure
GB9322828D0 (en) * 1993-11-05 1993-12-22 Sandoz Ltd Organic compounds
JP2001523083A (ja) * 1994-12-23 2001-11-20 スミスクライン・ビーチャム・コーポレイション Ｉｌ−５により媒介される疾病の治療に有用な組み換えｉｌ−５アンタゴニスト
US7399837B2 (en) * 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5783184A (en) * 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
US5693323A (en) * 1994-12-23 1997-12-02 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
GB9622386D0 (en) * 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
IT1296985B1 (it) * 1997-12-19 1999-08-03 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
WO2000042018A1 (en) * 1999-01-15 2000-07-20 Byk Gulden Lomberg Chemische Fabrik Gmbh Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity
CA2715683A1 (en) 1999-08-21 2001-03-01 Nycomed Gmbh Synergistic combination
AU2004226353A1 (en) 2003-04-01 2004-10-14 Laboratoires Serono Sa Inhibitors of phosphodiesterases in infertility
WO2008134721A1 (en) * 2007-04-30 2008-11-06 Smithkline Beecham Corporation Methods for administering anti-il-5 antibodies
AU2009228163B2 (en) * 2008-03-28 2012-08-30 Glaxosmithkline Llc Methods of treatment
CN102245625A (zh) 2008-10-17 2011-11-16 威斯康星旧生研究基金会 制备有生物活性的α-β肽的方法
US11390671B2 (en) 2017-06-06 2022-07-19 Glaxosmithkline Llc Biopharmaceutical compositions and methods for pediatric patients

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB645139A (en) * 1946-10-22 1950-10-25 Servita Gyogyszeryar Es Vegyip Improved process for the production of isoquinoline derivatives
DE1184344B (de) * 1962-06-16 1964-12-31 Orgamol Sa Verfahren zur Herstellung von Isochinolinderivaten
US3878215A (en) * 1971-12-01 1975-04-15 Sandoz Ag 2-Alkyl-3-substituted-4-aryl isoquinolines
DE2401453A1 (de) * 1973-01-16 1974-07-18 John James Voorhees Pharmazeutische zusammensetzung zur behandlung von hautproliferationserkrankungen
US4018927A (en) * 1973-12-17 1977-04-19 The Regents Of The University Of Michigan Treatment of proliferating skin diseases with papaverine alkaloids
DE2503156A1 (de) * 1974-02-05 1975-08-07 Sandoz Ag Verfahren zur herstellung neuer heterocyclischer verbindungen
DE2811361A1 (de) * 1978-03-16 1979-09-27 Hoechst Ag Neue isochinolinaldehyde und verfahren zu ihrer herstellung
DE3244594A1 (de) * 1982-12-02 1984-06-07 Hoechst Ag, 6230 Frankfurt 1-phenylisochinolinderivate und verfahren zu ihrer herstellung, diese verbindung enthaltende pharmazeutische praeparate und deren anwendung
HU196758B (en) * 1986-05-21 1989-01-30 Gyogyszerkutato Intezet Process for production of 3-hidroxi-methil-quinolines and medical compositions containing them
PH25651A (en) * 1986-05-21 1991-08-21 Duphar Int Res New di, tetrahydroisoquinoline derivatives

Also Published As

Publication number Publication date
SE8900039D0 (sv) 1989-01-05
FI90865B (fi) 1993-12-31
AT394365B (de) 1992-03-25
PL277092A1 (en) 1989-09-04
IT8947504A0 (it) 1989-01-04
HU205083B (en) 1992-03-30
PH25640A (en) 1991-08-21
IE890037L (en) 1989-07-08
JPH01213267A (ja) 1989-08-28
DK5789D0 (da) 1989-01-06
PT89405B (pt) 1993-09-30
NZ227561A (en) 1991-11-26
CA1332944C (en) 1994-11-08
DE3900233A1 (de) 1989-07-20
FI90865C (fi) 1994-04-11
PT89405A (pt) 1990-02-08
DK5789A (da) 1989-07-09
BE1002730A3 (fr) 1991-05-21
AU622429B2 (en) 1992-04-09
CH678727A5 (ko) 1991-10-31
IL88899A0 (en) 1989-08-15
GB2213482A (en) 1989-08-16
US4980359A (en) 1990-12-25
ZA89133B (en) 1990-09-26
LU87423A1 (fr) 1989-08-30
PL156099B1 (pl) 1992-02-28
FR2625743B1 (fr) 1990-11-09
IT1229523B (it) 1991-09-04
MY103963A (en) 1993-10-30
GR890100008A (el) 1994-03-31
SE501548C2 (sv) 1995-03-13
GB2213482B (en) 1991-09-11
GR1002750B (el) 1997-08-26
NL8900029A (nl) 1989-08-01
ES2010071A6 (es) 1989-10-16
AU2779589A (en) 1989-07-20
FI890072A (fi) 1989-07-09
IE61914B1 (en) 1994-11-30
JPH0649686B2 (ja) 1994-06-29
KR0142686B1 (ko) 1998-07-15
DE3900233C2 (de) 2000-04-27
FR2625743A1 (fr) 1989-07-13
IL88899A (en) 1994-07-31
GB8900102D0 (en) 1989-03-01
SE8900039L (sv) 1989-07-09
GB8800397D0 (en) 1988-02-10
ATA3589A (de) 1991-09-15
FI890072A0 (fi) 1989-01-06
HUT52061A (en) 1990-06-28

Similar Documents

Publication Publication Date Title
KR890011851A (ko) 이소 키놀린 유도체, 그 제조방법 및 사용방법
KR850003890A (ko) 1H-이미다조[4,5c]-퀴놀린-4-아민의 제조방법
MY100124A (en) Dihydropyridazinones.
GB1268243A (en) 0,2,4,5,-tetrahydro-3h,3-benzazepines
IE780515L (en) Morphine derivatives
KR860008111A (ko) 인딘과 나프탈렌 유도체의 제조방법
ES475173A1 (es) Procedimiento para la fabricacion de quinazolinas.
IE780514L (en) Morphine derivatives
KR890002168A (ko) 디하이드로-1,4-옥사지노[2,3-c]퀴놀린, 그의 제조방법 및 중간생성물 및 약제로서의 용도
GB1518042A (en) Oxadiazolinone derivatives
KR840009102A (ko) 치환된 이소퀴놀린 유도체의 제조방법
KR850000415A (ko) 퀴나졸리논 유도체의 제조방법
KR910000705A (ko) 신규한 벤즈이소퀴놀린 유도체 및 그의 제조 방법
GB1511187A (en) Chromans
KR920002594A (ko) 5-이소티아졸아민 유도체
JPS5283772A (en) 1,2,3,4-tetrahydroisoquinoline derivative and its salt
GB1321691A (en) Dihydro-3-piperidyl-2 3h-furanone derivatives
IE34081L (en) Butanolamines
ATE67197T1 (de) Thiadiazinon-derivate.
JPS52113979A (en) Novel 3,4-dihydrocarbostyril derivatives and method preparing the same
KR880002867A (ko) 옥사디아진 화합물의 제조방법
JPS525778A (en) N-substituted-1-oxo-1,2,3,4-tetrahydro-isoqvinoline derivatives
JPS52111578A (en) Novel benzomorphan derivatives
GB1472843A (en) Benzene sulphonamides
JPS5291867A (en) Preparation of indenopyridine derivatives

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

B701 Decision to grant
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee